Avyxa
As of the edition of 20 October 2026, Avyxa runs 12 drugs, 12 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Carboplatin | none listed | 0 |
| Gemcitabine | none listed | 1 |
| Docetaxel anhydrous | none listed | 0 |
| Fluorouracil | none listed | 2 |
| Etoposide | none listed | 5 |
| Leucovorin | none listed | 0 |
| Pemetrexed | none listed | 7 |
| Fulvestrant | none listed | 1 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Palonosetron | none listed | 3 |
| Fosaprepitant | none listed | 3 |
A route B row is one company at one target.